Publications

Detailed Information

Involvement of NF-κB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein : Involvement of NF-kappa B and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein

DC Field Value Language
dc.contributor.authorKim, Su-Hyeong-
dc.contributor.authorOh, Jung-Min-
dc.contributor.authorNo, Jae-Hong-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorJuhnn, Yong-Sung-
dc.contributor.authorSong, Yong-Sang-
dc.date.accessioned2012-05-31T08:10:28Z-
dc.date.available2012-05-31T08:10:28Z-
dc.date.created2018-01-19-
dc.date.issued2009-05-
dc.identifier.citationCarcinogenesis, Vol.30 No.5, pp.753-757-
dc.identifier.issn0143-3334-
dc.identifier.other24723-
dc.identifier.urihttps://hdl.handle.net/10371/76705-
dc.description.abstractThe human papillomavirus (HPV) E6 and E7 oncoproteins play important roles in cervical carcinogenesis through multiple mechanisms, including upregulation of cyclooxygenase-2 (COX-2), which has been shown to be involved in both carcinogenesis and cancer progression. To explore the role of E5 in cervical carcinogenesis, we herein investigated the effect of HPV 16 E5 on COX-2 expression. Our results revealed that E5 induced COX-2 expression through the epidermal growth factor receptor-signaling pathway, with nuclear factor-kappaB (NF-kappa B) and activator protein-1 (AP-1) acting as critical factors in E5-induced COX-2 expression. NF-kappa B inhibition blocked COX-2 expression more potently than inhibition of AP-1. Our findings collectively suggest that the HPV 16 E5 oncoprotein mediates cervical carcinogenesis at least in part via upregulation of COX-2 expression through NF-kappa B and AP-1, with NF-kappa B playing a larger role.-
dc.language영어-
dc.language.isoenko_KR
dc.publisherOxford University Press-
dc.titleInvolvement of NF-κB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein-
dc.title.alternativeInvolvement of NF-kappa B and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1093/carcin/bgp066-
dc.citation.journaltitleCarcinogenesis-
dc.description.citedreferenceSubbaramaiah K, 2007, CANCER RES, V67, P3976, DOI 10.1158/0008-5472.CAN-06-4273-
dc.description.citedreferenceIshikawa H, 2006, INT J RADIAT ONCOL, V66, P1347, DOI 10.1016/j.ijrobp.2006.07.007-
dc.description.citedreferenceKang SB, 2006, CANCER LETT, V237, P305, DOI 10.1016/j.canlet.2005.06.027-
dc.description.citedreferenceKim SH, 2006, CELL MOL LIFE SCI, V63, P930, DOI 10.1007/s00018-005-5561-x-
dc.description.citedreferenceKim SH, 2004, J CANCER RES CLIN, V130, P551, DOI 10.1007/s00432-004-0567-6-
dc.description.citedreferencePruthi RS, 2004, BJU INT, V93, P275, DOI 10.1111/j.1464-410X.2004.04601.x-
dc.description.citedreferenceHallak A, 2003, DIGEST DIS SCI, V48, P1998-
dc.description.citedreferenceKim MH, 2003, GYNECOL ONCOL, V90, P83, DOI 10.1016/S0090-8258(03)00224-5-
dc.description.citedreferenceSubbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96-
dc.description.citedreferenceSubbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200-
dc.description.citedreferenceZUR HH, 2002, NAT REV CANCER, V2, P342-
dc.description.citedreferenceZhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002-
dc.description.citedreferenceAnderson WF, 2002, CURR PHARM DESIGN, V8, P1035-
dc.description.citedreferenceSurh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X-
dc.description.citedreferenceGuo YS, 2001, J BIOL CHEM, V276, P22941-
dc.description.citedreferenceGaffney DK, 2001, INT J RADIAT ONCOL, V49, P1213-
dc.description.citedreferenceKulkarni S, 2001, CLIN CANCER RES, V7, P429-
dc.description.citedreferenceCrusius K, 1998, EXP CELL RES, V241, P76-
dc.description.citedreferenceRistimaki A, 1997, CANCER RES, V57, P1276-
dc.description.citedreferenceLuque I, 1997, SEMIN CANCER BIOL, V8, P103-
dc.description.citedreferenceZUR HH, 1994, ANNU REV MICROBIOL, V48, P427-
dc.description.citedreferenceSTRAIGHT SW, 1993, J VIROL, V67, P4521-
dc.description.citedreferenceWERNESS BA, 1990, SCIENCE, V248, P76-
dc.description.citedreferenceHAWLEYNELSON P, 1989, EMBO J, V8, P3905-
dc.description.citedreferenceKAUR P, 1989, J GEN VIROL, V70, P1261-
dc.description.citedreferenceDYSON N, 1989, SCIENCE, V243, P934-
dc.description.tc16-
dc.identifier.wosid000265740000005-
dc.identifier.scopusid2-s2.0-65549096389-
dc.citation.endpage757-
dc.citation.number5-
dc.citation.startpage753-
dc.citation.volume30-
dc.identifier.sci000265740000005-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.contributor.affiliatedAuthorJuhnn, Yong-Sung-
dc.contributor.affiliatedAuthorSong, Yong-Sang-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusHUMAN FORESKIN KERATINOCYTES-
dc.subject.keywordPlusGROWTH-FACTOR RECEPTOR-
dc.subject.keywordPlusCERVICAL-CANCER-
dc.subject.keywordPlusCYCLOOXYGENASE-2 EXPRESSION-
dc.subject.keywordPlusINDUCED APOPTOSIS-
dc.subject.keywordPlusEPITHELIAL-CELLS-
dc.subject.keywordPlusDOWN-REGULATION-
dc.subject.keywordPlusTYPE-16-
dc.subject.keywordPlusACTIVATION-
dc.subject.keywordPlusCARCINOMA-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share